Sana Biotechnology, Inc.
Financials
Valuation Metrics
Sana Biotechnology, Inc.'s Market Cap is $717M. At end of 2025 it was $1.03B. Ranked #2558 of 3,118 in US market (top 82%), #1075 of 1,474 on NASDAQ (top 73%), #195 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $717M | US#2,558/3,118 Sec#195/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-212M | US—/3,118 Sec—/265 |
| Total Assets | $432M | US#2,814/3,118 Sec#176/265 |
| Net Assets | $155M | US#2,730/3,118 Sec#201/265 |
| Employees | 142 | US#2,547/3,118 Sec#150/265 |
| Value | ||
| P/B | 4.64x | US#2,225/3,118 Sec#142/265 |
| FCF Yield | -18.84% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -137.04% | US#2,815/3,118 Sec#214/265 |
| ROA | -49.09% | US#2,979/3,118 Sec#212/265 |
| Financial Health | ||
| Debt Ratio | 179.18% | US#1,677/3,118 Sec#192/265 |
| Total Debt | $74M | US#2,506/3,118 Sec#135/265 |
| FCF | $-135M | US#2,695/3,118 Sec#169/265 |
| Cash | $57M | US#2,526/3,118 Sec#217/265 |
| Current Ratio | 1.38x | US#1,787/3,118 Sec#242/265 |
| Performance | ||
| 1Y Return | -51.62% | US#2,838/3,118 Sec#232/265 |
| 1M Return | -17.13% | US#2,543/3,118 Sec#189/265 |
| From 52W High | -63.44% | US#2,853/3,118 Sec#224/265 |
| 1Y MDD | -61.66% | US#2,765/3,118 Sec#211/265 |
| Trading | ||
| Volume | 2,246,413 shares | US#1,068/3,118 Sec#98/265 |
| Trading Value | $6M | US#2,664/3,118 Sec#215/265 |
| Per Share | ||
| EPS | $-0.71 | US—/3,118 Sec—/265 |
| BPS | $0.52 | US#2,744/3,118 Sec#217/265 |
Company Info
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.